【摘要】 目的评价替吉奥(S-1)联合顺铂治疗进展期胃癌的近期疗效及安全性。方法 56例进展期胃癌患者分为治疗组和对照组,各28例。治疗组方案为S-1 60 mg bid,d1~d21;顺铂静脉滴注60 mg·m-2,d1~d3,4周为1个周期。对照组方案为静脉滴注奥沙利铂125 mg·m-2,d1;静脉滴注替加氟600mg·m-2,d1~d5;静脉滴注亚叶酸钙120 mg·m-2,d1~d5,3周为1个周期。3个周期后评价2组疗效及不良反应。结果治疗组和对照组的客观有效率分别为75.0%和42.9%,差异有统计学意义(P<0.05);治疗组Ⅲ~Ⅳ级不良反应发生率明显低于对照组,差异有统计学意义(P<0.05)。结论 S-1联合顺铂化疗方案一线治疗进展期胃癌的近期疗效较好,不良反应可以耐受。更多还原

【Abstract】 Objective To evaluate the short- term efficacy and toxicity of the combination of gimeracil and oteracil porassium( S- 1) and cisplatin in the treatment of advanced gastric carcinoma. Methods Fifty- six patients with advanced gastric carcinoma were randomly divided into two groups with 28 cases in each group. Experimental group was treated with S- 1( 60 mg bid d1- d21) combined with cisplatin( 60 mg·m- 2iv d1- d3) with 4 weeks as a cycle. While control group was treated with oxaliplatin( 130 mg·m- 2iv d1),tegafur( 600 mg·m- 2iv d1- d5),calcium folinate( 120 mg ·m- 2iv d1- d5) with 3 weeks as a cycle.Short- term efficacy and adverse reactions were evaluated after three cycles. Results The tumor response rate of experimental group and control group was 75. 0% and 42. 9%( P <0. 05). Besides,compared with the control group,the occurrence of grade Ⅲ-Ⅳ adverse reactions in experimental group were apparently lower. Conclusion The regimen of S- 1 combined with cisplatin has shown a better efficacy in the treatment of patients with advanced gastric carcinoma,and the toxicity is relatively mild and tolerable.更多还原